124 related articles for article (PubMed ID: 11411549)
21. The effects of anti-hypertensive drugs and the mechanism of hypertension in vascular smooth muscle cell-specific ATP2B1 knockout mice.
Okuyama Y; Hirawa N; Fujita M; Fujiwara A; Ehara Y; Yatsu K; Sumida K; Kagimoto M; Katsumata M; Kobayashi Y; Saka S; Umemura S; Tamura K
Hypertens Res; 2018 Feb; 41(2):80-87. PubMed ID: 29046519
[TBL] [Abstract][Full Text] [Related]
22. Effect of antihypertensive treatments on insulin signalling in lympho-monocytes of essential hypertensive patients: a pilot study.
De Ciuceis C; Flati V; Rossini C; Rufo A; Porteri E; Di Gregorio J; Petroboni B; La Boria E; Donini C; Pasini E; Agabiti Rosei E; Rizzoni D
Blood Press; 2014 Dec; 23(6):330-8. PubMed ID: 24786779
[TBL] [Abstract][Full Text] [Related]
23. Bone morphogenetic protein-2 restores mineralization in glucocorticoid-inhibited MC3T3-E1 osteoblast cultures.
Luppen CA; Smith E; Spevak L; Boskey AL; Frenkel B
J Bone Miner Res; 2003 Jul; 18(7):1186-97. PubMed ID: 12854828
[TBL] [Abstract][Full Text] [Related]
24. New antihypertensive drugs. Angiotensin converting enzyme inhibitors and calcium antagonists.
Johnston CI
Aust Fam Physician; 1984 Apr; 13(4):278-83. PubMed ID: 6331357
[No Abstract] [Full Text] [Related]
25. AT
Bernhem K; Krishnan K; Bondar A; Brismar H; Aperia A; Scott L
BMC Cardiovasc Disord; 2017 May; 17(1):126. PubMed ID: 28514967
[TBL] [Abstract][Full Text] [Related]
26. Effect of benidipine hydrochloride, a dihydropyridine-type calcium antagonist, on the function of mouse osteoblastic cells.
Kosaka N; Uchii M
Calcif Tissue Int; 1998 Jun; 62(6):554-6. PubMed ID: 9576986
[TBL] [Abstract][Full Text] [Related]
27. The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family.
Kosaka H; Hirayama K; Yoda N; Sasaki K; Kitayama T; Kusaka H; Matsubara M
Eur J Pharmacol; 2010 Jun; 635(1-3):49-55. PubMed ID: 20307534
[TBL] [Abstract][Full Text] [Related]
28. In vivo receptor binding of benidipine and amlodipine in mesenteric arteries and other tissues of spontaneously hypertensive rats.
Yamada S; Nakajima M; Kusaka T; Uchida S; Kimura R
Life Sci; 2002 Mar; 70(17):1999-2011. PubMed ID: 12148692
[TBL] [Abstract][Full Text] [Related]
29. [Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD)].
Shibasaki Y; Nishiue T; Masaki H; Matsubara H; Iwasaka T
Nihon Rinsho; 2002 Oct; 60(10):1992-8. PubMed ID: 12397697
[TBL] [Abstract][Full Text] [Related]
30. Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.
Hulthén UL; Cao Z; Rumble JR; Cooper ME; Johnston CI
Am J Hypertens; 1996 Sep; 9(9):895-901. PubMed ID: 8879346
[TBL] [Abstract][Full Text] [Related]
31. Effects of short- and long-acting calcium channel blockers on the relationship between blood pressure and physical activity.
Kakinoki S; Nomura A; Takechi S; Kitabatake A
Am J Hypertens; 2001 Jan; 14(1):66-9. PubMed ID: 11206682
[TBL] [Abstract][Full Text] [Related]
32. Effects of Long- and Intermediate-Acting Dihydropyridine Calcium Channel Blockers in Hypertension: A Systematic Review and Meta-Analysis of 18 Prospective, Randomized, Actively Controlled Trials.
Chaugai S; Sherpa LY; Sepehry AA; Kerman SRJ; Arima H
J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):433-445. PubMed ID: 29739234
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease.
Abe M; Okada K; Maruyama T; Maruyama N; Matsumoto K
Hypertens Res; 2009 Apr; 32(4):270-5. PubMed ID: 19262495
[TBL] [Abstract][Full Text] [Related]
34. Antihypertensive drugs and fibrinolytic function.
Fogari R; Zoppi A
Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
[TBL] [Abstract][Full Text] [Related]
35. Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists.
Zannad F; Matzinger A; Larché J
Am J Hypertens; 1996 Jul; 9(7):633-43. PubMed ID: 8806975
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the cardioprotective and renoprotective effects of the L/N-type calcium channel blocker, cilnidipine, in adriamycin-treated spontaneously-hypertensive rats.
Aritomi S; Harada E; Sugino K; Nishimura M; Nakamura T; Takahara A
Clin Exp Pharmacol Physiol; 2015 Apr; 42(4):344-52. PubMed ID: 25582553
[TBL] [Abstract][Full Text] [Related]
37. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
Talbert RL
J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
[TBL] [Abstract][Full Text] [Related]
38. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis.
Candido R; Allen TJ; Lassila M; Cao Z; Thallas V; Cooper ME; Jandeleit-Dahm KA
Circulation; 2004 Mar; 109(12):1536-42. PubMed ID: 15023892
[TBL] [Abstract][Full Text] [Related]
39. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
Toba H; Yoshida M; Tojo C; Nakano A; Oshima Y; Kojima Y; Noda K; Wang J; Kobara M; Nakata T
Hypertens Res; 2011 Apr; 34(4):521-9. PubMed ID: 21270815
[TBL] [Abstract][Full Text] [Related]
40. Molecular and functional expression of voltage-operated calcium channels during osteogenic differentiation of human mesenchymal stem cells.
Zahanich I; Graf EM; Heubach JF; Hempel U; Boxberger S; Ravens U
J Bone Miner Res; 2005 Sep; 20(9):1637-46. PubMed ID: 16059635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
